A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now ...
who had seen an advantage for mepolizumab in terms of asthma control and reduction of exacerbations.17 It is important to note, however, that Bourdin et al, Cabon et al, and Busse et al re-analyzed existing phase-3 drug trial data by using the respective control groups as references to ...
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the outcome of the Pulmonary Allergy Drugs Advisory Committee of the United States (US) Food and Drug Administration (FDA) meeting on the use of mepolizumab as an add-on treatment to i...
The study population consisted of patients aged & GE;18 years who had a diagnosis of asthma and initiated mepolizumab after November 4, 2015 and had continuous medical and drug coverage in both the 365 days prior to and following mepolizumab initiation. In patients treated with mepolizumab, we ...
mepolizumab after 4 November 2015 and had continuous medical and drug coverage in both the 365 days prior to and following mepolizumab initiation, allowing for a 45-day enrollment gap; our data had end dates of the post-initiation period that varied by data partner (30 June 2019 to 31 May ...